Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Havrix Junior
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Havrix Junior is an inactivated hepatitis A vaccine used for active immunization against disease caused by hepatitis A virus (HAV). The vaccine works by causing the body to produce its own protection (antibodies) against this disease. It contains 720 ELISA units of killed hepatitis A virus (HM175 strain) in 0.5mL of liquid. Havrix Junior is specifically formulated for children and adolescents aged 1 to 15 years.
- Brand names
- Havrix JuniorHavrix 720 JuniorHavrix720 JuniorHavrix-720 Junior
Beyond the preview
Go deeper on Havrix Junior.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Havrix Junior.